All In Biotech

Drug Trial Radar · NCT06685757

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)

Last checked: Nov 20, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

132

Actual

Start

Dec 3, 2024

Primary completion

Dec 1, 2026

Study completion Jun 1, 2027

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Nov 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. Kidney transplants can save lives for people with kidney failure. But even after a successful transplant, the body's immune system can sometimes attack the new kidney. Antibody-mediated rejection (AMR) is when a person's immune system attacks a transplanted organ, like a new kidney. In the person receiving the transplant, their immune system creates specific antibodies. Antibodies are proteins that help the body fight infections. In people with AMR, these antibodies mistakenly see the new organ as a threat and damage its blood vessels. This can cause the new organ to fail. In this study, researchers will learn more about how a study drug called felzartamab affects people with AMR. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce antibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works in participants with kidney transplants who experience AMR compared to a placebo. A placebo is something that looks like the study drug but does not contain any medicine. A placebo is also given in the same way as the study drug. All participants in this study will have active AMR or AMR that has lasted for at least 6 months after their kidney transplant. The main question that researchers want to answer is: • How many participants have biopsy results showing that their transplanted kidney tissue looks normal or near normal after 24 weeks of treatment? Researchers will also learn about: * How long it takes before the participants' disease gets worse * How long the participants' urine protein levels stay low * Kidney biopsy scores to check for blood vessel inflammation at 6 months and 1 year * How many people have no blood vessel inflammation at these times * Changes in donor deoxyribonucleic acid (DNA) levels in blood from the start of treatment * Biopsy test scores for signs of rejection and inflammation at 6 months and 1 year * Changes in kidney function from the start of treatment * How many people have biopsy results showing their kidney tissue looks normal again * How long the transplanted kidney keeps working * How many participants have medical problems during the study * How many participants show signs of another type of kidney transplant rejection called T-cell-mediated rejection (TCMR) at Week 24 and Week 52 * How do results from vital signs, electrocardiograms (ECGs), and blood and urine tests change over time * How felzartamab is processed by the body * How many participants develop antibodies against felzartamab in the blood The study will be done as follows: * Participants will be screened to check if they can join the study. This will take up to 42 days. * There will be 2 parts in this study. * Part A of the study is "double blind." This means that neither the participants, study doctor, or site staff know if the participants received the study drug or a placebo. During Part A, participants will be randomized to receive up to 9 doses of either felzartamab or placebo. * Part B of the study is "open label." This means that the participants, study doctor, and site staff know which study drug the participant is receiving. During Part B, all participants from Part A will receive up to 9 doses of felzartamab. * All doses will be given through an "intravenous" infusion. This means it will be given into a vein. The dose the participants receive will depend on their body weight. * Part A will last up to 24 weeks. Part B will last up to 28 weeks. In total, participants will have up to 21 study visits and will be in the study for about 1 year.

Conditions

  • Antibody-mediated Rejection

Interventions

  • FelzartamabDrug

    Participants will receive felzartamab by intravenous infusion.

  • PlaceboDrug

    Participants will receive 0.9% saline solution by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percentage of Participants Who Achieve Biopsy-proven Histologic Resolution (BPHR)Time frame: Week 24

Locations

56 sites in 12 countries. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UCLA

    Los Angeles, California

  • Providence Healthcare

    Orange, California

  • Loma Linda

    San Bernardino, California

  • California Pacific Medical Center

    San Francisco, California

  • University of California, San Francisco

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • University of Chicago

    Chicago, Illinois

  • University of Kansas

    Kansas City, Kansas

  • Tulane University Health Sciences Center

    New Orleans, Louisiana

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • University of Nebraska

    Omaha, Nebraska

  • Cooperman Barnabas Medical Center

    West Orange, New Jersey

  • Duke University

    Durham, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Penn Medicine - Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Vanderbilt University

    Nashville, Tennessee

  • UT Southwestern Medical Center

    Dallas, Texas

  • Houston Methodist

    Houston, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • University of Washington Medical Center

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Clinica Privada Velez Sarsfield

    Córdoba, Argentina

  • Instituto de Trasplante y Alta Complejidad (ITAC)

    Cdad, Autónoma de Buenos Aires, Argentina

  • Princess Alexandra Hospital

    Woolloongabba, Australia

  • Royal Melbourne Hospital

    Parkville VIC, Australia, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Medical University of Vienna

    Spitalgasse, State of Vienna, Austria

  • Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vicente Scherer

    Centro Histórico, Porto Alegre - RS, Brazil

  • Hospital de Base da Faculdade de Medicina de São José do Rio Preto

    Vila São José, São José Do Rio Preto, Brazil

  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

    Cerqueira César, São Paulo, Brazil

  • Fundação Oswaldo Ramos - Hospital do Rim (HRIM)

    Vila Clementino, São Paulo, Brazil

  • University of Alberta

    Edmonton, Alberta, Canada

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada

  • The University of British Columbia (UBC)/St. Paul's Hospital part of Providence Health Care

    Vancouver, British Columbia, Canada

  • McGill University

    Montreal, Quebec, Canada

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.